A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 11, Pages e003261
Publisher
BMJ
Online
2021-11-19
DOI
10.1136/jitc-2021-003261
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
- (2021) Marta Ligero et al. RADIOLOGY
- A deep look into radiomics
- (2021) Camilla Scapicchio et al. Radiologia Medica
- Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
- (2020) Daan Jan Willem Rauwerdink et al. ANNALS OF SURGICAL ONCOLOGY
- Radiomics, tumor volume and blood biomarkers for early prediction of pseudoprogression in metastatic melanoma patients treated with immune checkpoint inhibition
- (2020) Lucas Basler et al. CLINICAL CANCER RESEARCH
- Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers
- (2019) S Trebeschi et al. ANNALS OF ONCOLOGY
- Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
- (2019) Nathalie Harder et al. Scientific Reports
- Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy
- (2019) Amadeus Schraag et al. EUROPEAN JOURNAL OF RADIOLOGY
- Epidemiology and Risk Factors of Melanoma
- (2019) Stephanie Carr et al. SURGICAL CLINICS OF NORTH AMERICA
- Prognostic value of radiomic analysis of iodine overlay maps from dual-energy computed tomography in patients with resectable lung cancer
- (2018) Jooae Choe et al. EUROPEAN RADIOLOGY
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
- (2018) Roger Sun et al. LANCET ONCOLOGY
- Can radiomics personalise immunotherapy?
- (2018) Issam El Naqa et al. LANCET ONCOLOGY
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Analysis of Trends in US Melanoma Incidence and Mortality
- (2017) Alex M. Glazer et al. JAMA Dermatology
- Radiomics: Images Are More than Pictures, They Are Data
- (2016) Robert J. Gillies et al. RADIOLOGY
- Pathologic stratification of operable lung adenocarcinoma using radiomics features extracted from dual energy CT images
- (2016) Jung Min Bae et al. Oncotarget
- Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment
- (2015) Elin S. Gray et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Dual-Energy CT: General Principles
- (2012) Thorsten R. C. Johnson AMERICAN JOURNAL OF ROENTGENOLOGY
- Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?
- (2011) G. Schmid-Bindert et al. EUROPEAN RADIOLOGY
- Strategies for early melanoma detection: Approaches to the patient with nevi
- (2009) Agnessa Gadeliya Goodson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started